Opus Genetics Reports Positive Phase 3 Results For Night Vision Therapy, Stock Up

(RTTNews) - Opus Genetics (IRD), Monday announced encouraging topline results from its pivotal Phase 3 LYNX-2 trial, evaluating Phentolamine Ophthalmic Solution 0.75 percent for chronic night driving impairment in patients with reduced vision following keratorefractive surgeries like LASIK or PRK.

The treatment met its primary endpoint, with 17.3 percent of patients achieving a 15-letter improvement in low-light visual acuity after 15 days, compared to 9.2 percent in the placebo group. Patients also reported better night-driving performance, such as reduced glare from headlights.

Phentolamine works by reducing pupil size without engaging the ciliary muscle, offering a safer alternative to older treatments. The trial showed no new safety concerns, and no evidence of diminished effect through six weeks.

IRD is currently trading at $1.23, up $0.23 or 23.79 percent on the Nasdaq.